{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T13:03:16Z","timestamp":1792328596968,"version":"4.4.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2012,5,3]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Patients with stable coronary artery disease on single\u2010antiplatelet therapy with aspirin are still at risk for atherothrombotic events, and high on\u2010aspirin residual platelet reactivity (RPR) has been suggested as a risk factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      In this randomized trial, the association between platelet function determined by the PFA100 platelet function analyzer system (Siemens Healthcare Diagnostics, Germany) and clinical outcome in 1001 patients, all on single\u2010antiplatelet therapy with aspirin (160 mg\/d) was studied. Patients were randomized to continue with aspirin 160\u00a0mg\/d or change to clopidogrel 75\u00a0mg\/d. A composite end point of death, myocardial infarction, ischemic stroke, and unstable angina was used. At 2\u2010year follow\u2010up, 106 primary end points were registered. The prevalence of high RPR was 25.9%. High on\u2010aspirin RPR did not significantly influence the primary end point in the aspirin group (13.3% versus 9.9%,\n                      <jats:italic>P<\/jats:italic>\n                      =0.31). However, in post hoc analysis, patients with von Willebrand factor levels or platelet count below median values and high on\u2010aspirin RPR had a statistically significant higher end point rate than that of patients with low RPR (20% versus 7.5%,\n                      <jats:italic>P<\/jats:italic>\n                      =0.014, and 18.2% versus 10.8%,\n                      <jats:italic>P<\/jats:italic>\n                      =0.039, respectively). The composite end point rate in patients with high on\u2010aspirin RPR treated with clopidogrel was not different from that of patients treated with aspirin (7.6% versus 13.3%,\n                      <jats:italic>P<\/jats:italic>\n                      =0.16).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">In stable, aspirin\u2010treated patients with coronary artery disease, high on\u2010aspirin RPR did not relate to clinical outcome and did not identify a group responsive to clopidogrel. Post hoc subgroup analysis raised the possibility that high on\u2010aspirin RPR might be predictive in patients with low von Willebrand factor or platelet count, but these findings will require confirmation in future studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      Unique identifier: NCT00222261.\n                      <jats:bold>\n                        (\n                        <jats:italic>J Am Heart Assoc<\/jats:italic>\n                        . 2012;1:e000703 doi: 10.1161\/JAHA.112.000703.)\n                      <\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.112.000703","type":"journal-article","created":{"date-parts":[[2012,5,28]],"date-time":"2012-05-28T10:58:27Z","timestamp":1338202707000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":73,"title":["High On\u2010Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)"],"prefix":"10.1161","volume":"1","author":[{"given":"Alf\u2010\u00c5ge R.","family":"Pettersen","sequence":"first","affiliation":[{"name":"From the Center for Clinical Heart Research,\rOslo University Hospital,\rUllevaal"},{"name":"Department of Cardiology,\rOslo University Hospital,\rUllevaal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingebj\u00f8rg","family":"Seljeflot","sequence":"additional","affiliation":[{"name":"From the Center for Clinical Heart Research,\rOslo University Hospital,\rUllevaal"},{"name":"Department of Cardiology,\rOslo University Hospital,\rUllevaal"},{"name":"and Faculty of Medicine,\rUniversity of Oslo,\rOslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abdelnoor","sequence":"additional","affiliation":[{"name":"Section for Epidemiology and Statistics,\rOslo University Hospital,\rUllevaal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Arnesen","sequence":"additional","affiliation":[{"name":"From the Center for Clinical Heart Research,\rOslo University Hospital,\rUllevaal"},{"name":"Department of Cardiology,\rOslo University Hospital,\rUllevaal"},{"name":"and Faculty of Medicine,\rUniversity of Oslo,\rOslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02498.x"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(11)70017-2"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm226"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100802485947"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04115.x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-02-0082"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.160481"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00405-X"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.181"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.013"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.10.011"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(93)90164-J"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39430.529549.BE"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.05.041"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm232"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01351.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.047"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)03014-0"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.040"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-9-4"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/14017430410024324"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/9.1.97"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00529-2"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn554"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa053935"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.675587"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.047"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100120104890"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2010.543710"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614626"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.12.034"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000047041.66447.29"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.112.000703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:39:11Z","timestamp":1715582351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.112.000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5,3]]}},"alternative-id":["10.1161\/JAHA.112.000703"],"URL":"https:\/\/doi.org\/10.1161\/jaha.112.000703","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,3]]},"assertion":[{"value":"2012-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e000703"}}